Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: consultee and commentator comments on the ACD

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Nursing
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Pathologists
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Department of Health
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: NHS Birmingham East and North
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Commissioning Support Appraisal Service
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: addendum by Liverpool Research Implementation Group (LRiG)

This page was last updated: 29 October 2012